LLY

713.6

-0.54%↓

JNJ

152.71

+0.53%↑

ABBV

182.24

+0.74%↑

NVO

67.5

+0.28%↑

UNH

297.4

-0.69%↓

LLY

713.6

-0.54%↓

JNJ

152.71

+0.53%↑

ABBV

182.24

+0.74%↑

NVO

67.5

+0.28%↑

UNH

297.4

-0.69%↓

LLY

713.6

-0.54%↓

JNJ

152.71

+0.53%↑

ABBV

182.24

+0.74%↑

NVO

67.5

+0.28%↑

UNH

297.4

-0.69%↓

LLY

713.6

-0.54%↓

JNJ

152.71

+0.53%↑

ABBV

182.24

+0.74%↑

NVO

67.5

+0.28%↑

UNH

297.4

-0.69%↓

LLY

713.6

-0.54%↓

JNJ

152.71

+0.53%↑

ABBV

182.24

+0.74%↑

NVO

67.5

+0.28%↑

UNH

297.4

-0.69%↓

Search

Pfizer

Fermé

SecteurSoins de santé

23.02 0.22

Résumé

Variation du prix de l'action

24h

Actuel

Min

22.81

Max

23.15

Chiffres clés

By Trading Economics

Revenu

2.6B

3B

Ventes

-4B

14B

P/E

Moyenne du Secteur

16.667

54.533

BPA

0.92

Rendement du dividende

7.48

Marge bénéficiaire

21.633

Employés

81,000

EBITDA

2B

4.5B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+42.97% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

7.48%

2.41%

Prochains Résultats

29 juil. 2025

Date du Prochain Dividende

13 juin 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-15B

131B

Ouverture précédente

22.8

Clôture précédente

23.02

Sentiment de l'Actualité

By Acuity

44%

56%

160 / 382 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Pfizer Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

20 mai 2025, 04:13 UTC

Principaux Mouvements du Marché

Biotech Company 3SBio's Shares Surge After $6 Billion Licensing Deal With Pfizer

1 mai 2025, 18:41 UTC

Principaux Mouvements du Marché

Arvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets Challenges

29 avr. 2025, 11:24 UTC

Résultats

Pfizer 1Q Revenue Slides as Paxlovid Sales Fade

20 mai 2025, 14:46 UTC

Acquisitions, Fusions, Rachats

Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid. -- Barrons.com

15 mai 2025, 15:20 UTC

Actualités

New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel -- WSJ

12 mai 2025, 22:14 UTC

Actualités

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mai 2025, 18:45 UTC

Actualités

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mai 2025, 17:14 UTC

Actualités

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

12 mai 2025, 09:02 UTC

Actions en Tendance

Stocks to Watch: Amazon, Tesla, Apple, Maersk -- WSJ

7 mai 2025, 17:01 UTC

Actualités

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7 mai 2025, 09:30 UTC

Actualités

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

5 mai 2025, 15:13 UTC

Market Talk
Résultats

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

1 mai 2025, 14:07 UTC

Résultats

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mai 2025, 11:58 UTC

Résultats

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mai 2025, 11:06 UTC

Résultats

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mai 2025, 10:48 UTC

Résultats

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

29 avr. 2025, 19:47 UTC

Résultats

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

29 avr. 2025, 18:11 UTC

Résultats

Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com

29 avr. 2025, 15:22 UTC

Résultats

Pfizer Earnings Beat Isn't Enough to Ease Stock Worries -- Barrons.com

29 avr. 2025, 12:03 UTC

Acquisitions, Fusions, Rachats

Pfizer Files 8K - Costs of Exits Or Disposals >PFE

29 avr. 2025, 11:46 UTC

Résultats

Pfizer Stock Gains After Earnings Beat. Tariffs Aren't the Only Worry for Wall Street. -- Barrons.com

29 avr. 2025, 11:42 UTC

Résultats

Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com

29 avr. 2025, 11:12 UTC

Résultats

Pfizer Earnings Beat. Tariffs Uncertainty Hinders Guidance. -- Barrons.com

29 avr. 2025, 10:52 UTC

Résultats

Pfizer: Currently Trending Towards Upper End of 2025 Adj EPS Guidance Range

29 avr. 2025, 10:51 UTC

Résultats

Pfizer: Believe We Can Be Agile in Navigating Uncertain and Volatile External Environment

29 avr. 2025, 10:50 UTC

Résultats

Pfizer: On Track For Total Net Cost Savings $5.7B Through 2027

29 avr. 2025, 10:47 UTC

Résultats

Pfizer: Expects to Continue to De-Lever in Prudent Manner

29 avr. 2025, 10:47 UTC

Résultats

Pfizer: Current Fincl Guidance Does Not Anticipate Any Share Repurchases in 2025

29 avr. 2025, 10:46 UTC

Résultats

Pfizer: "Unable to Predict" Tariff Impact "At This Time"

29 avr. 2025, 10:45 UTC

Résultats

Pfizer: Reaffirmed Views Don't Currently Include Impact From Tariffs

Comparaison

Variation de prix

Pfizer prévision

Objectif de Prix

By TipRanks

42.97% hausse

Prévisions sur 12 Mois

Moyen 32.94 USD  42.97%

Haut 115 USD

Bas 23 USD

Basé sur 18 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

18 ratings

5

Achat

13

Maintien

0

Vente

Score Technique

By Trading Central

22.855 / 23.85Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

160 / 382Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.